FDA Clears Path for Key Phase 3 Trial of Lacutamab in CTCL Treatment
Innate Pharma is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF).
/ 2 items